Results 51 to 60 of about 3,103 (173)

Using PBPK to Simulate Target Biopredictive Dissolution Profiles for Long‐Acting Injectables ‐ Where to Begin With Critical Bioavailability Attributes?

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Long‐acting injectables (LAI) are of increasing interest as they facilitate improved medication adherence and exposure, with target plasma concentration levels maintained over weeks/months. Biopredictive in vitro dissolution tests can aid formulation development of LAIs and guide quality control dissolution testing by facilitating accelerated ...
Hannah Cleary, Nikoletta Fotaki, Tim Persoons, Deirdre M. D'Arcy   +3 more
wiley   +1 more source

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

HIV Medicine, Volume 27, Issue 3, Page 386-396, March 2026.
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
M. Gartland, X. Wang, Q. Liao, B. Li, F. Du, M. Krystal, A. R. Tenorio, A. Pierce, J. R. Castillo‐Mancilla   +8 more
wiley   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source

The HIV/AIDS response as we knew it is over: Where do we go from here?

Journal of the International AIDS Society, Volume 29, Issue 2, February 2026.
Abstract Introduction The global HIV response, once a model of progress and innovation, faces a profound moment. Despite four decades of pivotal scientific and programmatic advances—most notably in antiretroviral therapy (ART) and pre‐exposure prophylaxis (PrEP)—the world remains off track to meet the 2025 and 2030 targets for ending AIDS as a public ...
Chris Beyrer, Jirair Ratevosian, Tom Carpino, Nora E. Rosenberg, Huub C. Gelderblom, Patrick S. Sullivan, Steve G. Deeks, Glenda Gray   +7 more
wiley   +1 more source

Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB‐Brasil study

Journal of the International AIDS Society
Introduction Although the efficacy of long‐acting injectable cabotegravir (CAB‐LA) for pre‐exposure prophylaxis (PrEP) is well‐known from clinical trials, research is needed to guide effective strategies for its implementation.
Cristina Pimenta, Claudio G. Mann, Brenda Hoagland, Eduardo Carvalheira, Cristina Jalil, Marcos Benedetti, Nilo Fernandes, Carolina Coutinho, Emilia M. Jalil, Mayara Secco Torres Silva, Roberta Trefiglio, Alessandro Farias, Maria Paula G. Mourão, José Valdez Madruga, Josué N. deLima, Ronaldo Zonta, Gabrielle O'Malley, Valdilea G. Veloso, Beatriz Grinsztejn, Thiago S. Torres, for the ImPrEP CAB‐Brasil Study   +20 more
doaj   +1 more source

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management

Zhongguo linchuang yanjiu
Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS.
HU Zhiliang, YANG Yongfeng
doaj   +1 more source

Long‐Acting Technologies to Prevent HIV: Why Is the Asia‐Pacific Being Left Behind?

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
Giten Khwairakpam, Caroline Thomas, Anushiya Karunanithy, Rena Janamnuaysook, Rajkumar Nalinikanta, South Asia and South‐East Asia (SASEA) Partnership Platform   +5 more
wiley   +1 more source

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow, Amanda Binkley, Jessica Meisner, Samantha Huo, Matthew Hinton   +4 more
wiley   +1 more source

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society
Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL]
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
doaj   +1 more source

Pittsburgh Sleep Quality Index (PSQI) Changes in Virologically Suppressed People Living with HIVSwitching to Long-Acting Cabotegravir and Rilpivirine

Biomedicines
Background: Limited evidence is available about sleep quality changes associated with the use of Cabotegravir (CAB), a new, long-acting (LA) antiretroviral (ARV) drug belonging to the class of Integrase Strand Transfer Inhibitors (INSTIs).
Nicolò De Gennaro, Mariacristina Poliseno, Angelo Dargenio, Flavia Balena, Deborah Fiordelisi, Vito Spada, Greta Romita, Giacomo Guido, Francesco Di Gennaro, Giuseppe Bruno, Mariantonietta Purgatorio, Giovanni Battista Buccoliero, Annalisa Saracino   +12 more
doaj   +1 more source